Gilead Sciences GILD
NASDAQ GILD
$144.80 -0.85 (-0.58%)
As of: Sep 10, 2026 · 3:59 PM EDT

Gilead Sciences (GILD) Assets (2009 - 2026)

Gilead Sciences' (GILD) quarterly Assets came in at $49.4 billion in Q2 2026, down 11.41% on a YoY basis from $55.7 billion in Q2 2025, and down 12.29% quarter-over-quarter from $56.3 billion in Q1 2026.

Analysis

Gilead Sciences (GILD) Assets (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has reported Assets for 18 consecutive years, with $49.4 billion the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Assets fell 11.41% year-over-year to $49.4 billion; the trailing twelve-month figure through Jun 2026 stood at $49.4 billion (down 11.41% YoY), and the FY2025 full-year result was $59.0 billion, changed 0.05% from the prior year.
  • Assets slipped to $49.4 billion in Q2 2026 per GILD's latest filing, from $56.3 billion in the prior quarter.
  • Across five years, Assets topped out at $63.2 billion in Q4 2022 and bottomed at $49.4 billion in Q2 2026.
  • Historically, Assets has averaged $58.8 billion across 5 years, with a median of $59.0 billion in 2024.
  • The sharpest annual moves came in 2024 and 2025: Assets fell 14.05% in 2024, then climbed 7.35% in 2025.
  • Over 5 years, Assets stood at $63.2 billion in 2022, then decreased by 1.66% to $62.1 billion in 2023, then fell by 5.04% to $59.0 billion in 2024, then increased by 0.05% to $59.0 billion in 2025, then declined by 16.37% to $49.4 billion in 2026.
  • According to Business Quant data, Assets over the past three periods registered $49.4 billion, $56.3 billion, and $59.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Assets (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 95.64 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 49.36 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 27.42 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 41.73 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 10.03 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 10.96 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 5.56 Bn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 32.09 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 5.31 Bn
10 Insmed 27.67 Bn 26.51 Bn 358.27 Mn 2.10 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 49.36 Bn
Mar 31, 2026 56.28 Bn
Dec 31, 2025 59.02 Bn
Sep 30, 2025 58.53 Bn
Jun 30, 2025 55.72 Bn
Mar 31, 2025 56.43 Bn
Dec 31, 2024 59.00 Bn
Sep 30, 2024 54.53 Bn
Jun 30, 2024 53.58 Bn
Mar 31, 2024 56.29 Bn
Dec 31, 2023 62.13 Bn
Sep 30, 2023 62.37 Bn
Jun 30, 2023 62.34 Bn
Mar 31, 2023 61.88 Bn
Dec 31, 2022 63.17 Bn
Sep 30, 2022 62.56 Bn
Jun 30, 2022 62.87 Bn
Mar 31, 2022 63.08 Bn
Dec 31, 2021 67.95 Bn
Sep 30, 2021 67.10 Bn